Concord Biotech announces 1:1 bonus issue
Concord Biotech (CONCORDBIO) said it will issue bonus shares in the ratio 1:1. The company is valued at about ₹14,388 crore.
What happened
In a filing with the BSE on 27 October 2026 at 07:27 PM, Concord Biotech (CONCORDBIO) said that it will issue bonus shares in the ratio 1:1.
Company snapshot
Concord Biotech is a small-cap company in the Healthcare sector, with a market value of about ₹14,388 crore.
The stock last traded at ₹1,375.3, against a 52-week range of ₹987–₹1,615 (14.8% below the high).
Before this filing the shares had moved −19.8% over the month and −1.5% over three months. Average daily turnover over the last 20 sessions was about ₹13.89 crore.
Promoters held 44.08% at the end of Q1 FY27. Foreign institutions owned 7.52% and domestic institutions 9.36%.
| Quarter | Revenue | Net profit | EPS (₹) |
|---|---|---|---|
| Q1 FY26 | 204 | 44.1 | 4.21 |
| Q2 FY26 | 247 | 63.6 | 6.03 |
| Q3 FY26 | 278 | 64.5 | 6.08 |
| Q4 FY26 | 326 | 88.8 | 8.46 |
| Q1 FY27 | 257 | 58.5 | 5.52 |
What history shows
BCEIE's records show 1 previous bonus issue filing from the company since May 2026.
Market-wide, 57 bonus issue filings with an impact score of 50 or more saw an average next-day move of +1.0%, with 58% rising.
Past reactions describe what happened before; they are not a forecast.
What to watch
- 27 October 2026: Board meeting — Financial Results.
In the news
Recent coverage elsewhere (links open the original publisher):
- Concord Biotech shareholders approve bonus issue and capital hike
- Concord Biotech - Positive Breakout: These 5 stocks cross above their 200 DMAs
- Concord Biotech Ltd Faces Technical Downgrade Amid Bearish Momentum
- Concord Biotech Ltd Technical Momentum Shifts Amid Mixed Market Signals
- Concord Biotech Ltd Faces Mildly Bearish Technical Shift Amid Mixed Momentum Signals
Source
Automatically written from the exchange filing and BCEIE data. Not investment advice. Check the original filing before acting on it.